Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 301 to 308 of 308

Type: GuidanceRemove Type: Guidance filter
Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter
Guidance programme: Interventional procedures guidanceRemove Guidance programme: Interventional procedures guidance filter
Guidance programme: Medical technologies guidanceRemove Guidance programme: Medical technologies guidance filter
Guidance programme: Diagnostics guidanceRemove Guidance programme: Diagnostics guidance filter
Guidance programme: Highly specialised technologies guidanceRemove Guidance programme: Highly specialised technologies guidance filter
Guidance programme: Antimicrobial prescribing guidelinesRemove Guidance programme: Antimicrobial prescribing guidelines filter
Guidance programme: Cancer service guidelinesRemove Guidance programme: Cancer service guidelines filter
Guidance programme: Clinical guidelinesRemove Guidance programme: Clinical guidelines filter
Guidance programme: Medicines practice guidelinesRemove Guidance programme: Medicines practice guidelines filter
Guidance programme: Public health guidelinesRemove Guidance programme: Public health guidelines filter
Guidance programme: Safe staffing guidelinesRemove Guidance programme: Safe staffing guidelines filter
Guidance programme: Social care guidelinesRemove Guidance programme: Social care guidelines filter

Guidance and quality standards awaiting development
Title	Type
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902	Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477	Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952	Technology appraisal guidance
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments TSID 11915	Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998	Technology appraisal guidance
Zuranolone for treating severe postnatal depression ID6431	Technology appraisal guidance

Results per page

10
25
50
All